Related Experiment Video
Updated: Jul 25, 2026
12:37
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
Flosequinan in chronic heart failure: how is exercise capacity improved?
A P Banning1, M W Ramsey, E A Jones
1Department of Cardiology, University of Wales College of Medicine, Cardiff, UK.
European Journal of Clinical Pharmacology
|January 1, 1996
Summary
Flosequinan improved exercise duration in patients with chronic heart failure. However, this drug was later withdrawn due to increased mortality, despite initial findings of symptomatic benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Standard therapy for chronic heart failure includes diuretics, angiotensin converting enzyme (ACE) inhibitors, and digoxin.
- Flosequinan has shown potential to enhance exercise duration and improve symptoms when added to standard heart failure treatment.
- The precise clinical pharmacology of flosequinan requires further elucidation.
Purpose of the Study:
- To investigate the effects of flosequinan on exercise duration and large artery distensibility in patients with chronic heart failure.
- To assess the clinical pharmacology of flosequinan in patients with symptomatic chronic heart failure despite standard therapy.
Main Methods:
- A double-blind, placebo-controlled, parallel-group study involving 24 patients with chronic heart failure.
- Patients received either 100 mg daily of flosequinan or a placebo.
- Cardiorespiratory exercise testing and Doppler ultrasound were used to measure changes in exercise duration and large artery distensibility, respectively.
Main Results:
- Flosequinan treatment significantly increased exercise duration by 14% compared to placebo after 8 weeks.
- This improvement in exercise duration was associated with a significant reduction in the VE/VCO2 slope (-16%).
- Flosequinan did not alter brachial-radial pulse wave velocities, indicating no significant change in large artery distensibility.
Conclusions:
- Flosequinan effectively improves exercise duration in patients with chronic heart failure.
- The beneficial effect on exercise duration appears independent of changes in large artery distensibility and potentially independent of vasodilation when used with ACE inhibitors.
- Despite initial positive findings on symptomatic improvement, subsequent trials revealed increased mortality with flosequinan, leading to its withdrawal from clinical use.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:17Exercise and Cardiac Output
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be met...
Sustained exercise increases the muscles' oxygen demand, which can be met...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...